tetano
Editor, Senior Moderator
Sci Rep
. 2022 Dec 13;12(1):21491.
doi: 10.1038/s41598-022-26072-7.
ACE2 polymorphisms impact COVID-19 severity in obese patients
Nour Jalaleddine[SUP] 1 [/SUP], Amal Bouzid[SUP] 2 [/SUP], Mahmood Hachim[SUP] 1 [/SUP], Narjes Saheb Sharif-Askari[SUP] 2 [/SUP], Bassam Mahboub[SUP] 2 3 [/SUP], Abiola Senok[SUP] 1 [/SUP], Rabih Halwani[SUP] 2 4 5 [/SUP], Rifat A Hamoudi[SUP] 2 6 [/SUP], Saba Al Heialy[SUP] 7 8 [/SUP]
Affiliations
Abstract
A strong association between obesity and COVID-19 complications and a lack of prognostic factors that explain the unpredictable severity among these patients still exist despite the various vaccination programs. The expression of angiotensin converting enzyme 2 (ACE2), the main receptor for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is enhanced in obese individuals. The occurrence of frequent genetic single nucleotide polymorphisms (SNPs) in ACE2 is suggested to increase COVID-19 severity. Accordingly, we hypothesize that obesity-associated ACE2 polymorphisms increase the severity of COVID-19. In this study, we profiled eight frequently reported ACE2 SNPs in a cohort of lean and obese COVID-19 patients (n = 82). We highlight the significant association of rs2285666, rs2048683, rs879922, and rs4240157 with increased severity in obese COVID-19 patients as compared to lean counterparts. These co-morbid-associated SNPs tend to positively correlate, hence proposing possible functional cooperation to ACE2 regulation. In obese COVID-19 patients, rs2285666, rs879922, and rs4240157 are significantly associated with increased blood nitrogen urea and creatinine levels. In conclusion, we highlight the contribution of ACE2 SNPs in enhancing COVID-19 severity in obese individuals. The results from this study provide a basis for further investigations required to shed light on the underlying mechanisms of COVID-19 associated SNPs in COVID-19 obese patients.
. 2022 Dec 13;12(1):21491.
doi: 10.1038/s41598-022-26072-7.
ACE2 polymorphisms impact COVID-19 severity in obese patients
Nour Jalaleddine[SUP] 1 [/SUP], Amal Bouzid[SUP] 2 [/SUP], Mahmood Hachim[SUP] 1 [/SUP], Narjes Saheb Sharif-Askari[SUP] 2 [/SUP], Bassam Mahboub[SUP] 2 3 [/SUP], Abiola Senok[SUP] 1 [/SUP], Rabih Halwani[SUP] 2 4 5 [/SUP], Rifat A Hamoudi[SUP] 2 6 [/SUP], Saba Al Heialy[SUP] 7 8 [/SUP]
Affiliations
- PMID: 36513710
- DOI: 10.1038/s41598-022-26072-7
Abstract
A strong association between obesity and COVID-19 complications and a lack of prognostic factors that explain the unpredictable severity among these patients still exist despite the various vaccination programs. The expression of angiotensin converting enzyme 2 (ACE2), the main receptor for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), is enhanced in obese individuals. The occurrence of frequent genetic single nucleotide polymorphisms (SNPs) in ACE2 is suggested to increase COVID-19 severity. Accordingly, we hypothesize that obesity-associated ACE2 polymorphisms increase the severity of COVID-19. In this study, we profiled eight frequently reported ACE2 SNPs in a cohort of lean and obese COVID-19 patients (n = 82). We highlight the significant association of rs2285666, rs2048683, rs879922, and rs4240157 with increased severity in obese COVID-19 patients as compared to lean counterparts. These co-morbid-associated SNPs tend to positively correlate, hence proposing possible functional cooperation to ACE2 regulation. In obese COVID-19 patients, rs2285666, rs879922, and rs4240157 are significantly associated with increased blood nitrogen urea and creatinine levels. In conclusion, we highlight the contribution of ACE2 SNPs in enhancing COVID-19 severity in obese individuals. The results from this study provide a basis for further investigations required to shed light on the underlying mechanisms of COVID-19 associated SNPs in COVID-19 obese patients.